127 related articles for article (PubMed ID: 22076465)
21. Inhibition of MCL-1 by obatoclax sensitizes Sp2/0-Ag14 hybridoma cells to glutamine deprivation-induced apoptosis.
Harnett CC; Abusneina A; Clément J; Gauthier ER
Cell Biochem Funct; 2015 Jul; 33(5):334-40. PubMed ID: 26178811
[TBL] [Abstract][Full Text] [Related]
22. The BH3-mimetic ABT-737 induces mast cell apoptosis in vitro and in vivo: potential for therapeutics.
Karlberg M; Ekoff M; Huang DC; Mustonen P; Harvima IT; Nilsson G
J Immunol; 2010 Aug; 185(4):2555-62. PubMed ID: 20639495
[TBL] [Abstract][Full Text] [Related]
23. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.
Yecies D; Carlson NE; Deng J; Letai A
Blood; 2010 Apr; 115(16):3304-13. PubMed ID: 20197552
[TBL] [Abstract][Full Text] [Related]
24. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.
Kohl TM; Hellinger C; Ahmed F; Buske C; Hiddemann W; Bohlander SK; Spiekermann K
Leukemia; 2007 Aug; 21(8):1763-72. PubMed ID: 17554384
[TBL] [Abstract][Full Text] [Related]
25. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
Kuroda J; Kimura S; Strasser A; Andreeff M; O'Reilly LA; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Tabe Y; Taniwaki M; Maekawa T
Cell Death Differ; 2007 Sep; 14(9):1667-77. PubMed ID: 17510658
[TBL] [Abstract][Full Text] [Related]
26. ABT-737, proving to be a great tool even before it is proven in the clinic.
Vaux DL
Cell Death Differ; 2008 May; 15(5):807-8. PubMed ID: 18408737
[No Abstract] [Full Text] [Related]
27. The Bcl-2 homology domain 3 (BH3) mimetic ABT-737 reveals the dynamic regulation of bad, a proapoptotic protein of the Bcl-2 family, by Bcl-xL.
Ezzoukhry Z; Louandre C; François C; Saidak Z; Godin C; Mazière JC; Galmiche A
Mol Pharmacol; 2011 Jun; 79(6):997-1004. PubMed ID: 21393385
[TBL] [Abstract][Full Text] [Related]
28. Synergistic Bcl-2 inhibition by ABT-737 and cyclosporine A.
Cippà PE; Kamarashev J; Chen J; Kraus AK; Segerer S; Feldmeyer L; Fehr T
Apoptosis; 2013 Mar; 18(3):315-23. PubMed ID: 23208368
[TBL] [Abstract][Full Text] [Related]
29. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells.
Kline MP; Rajkumar SV; Timm MM; Kimlinger TK; Haug JL; Lust JA; Greipp PR; Kumar S
Leukemia; 2007 Jul; 21(7):1549-60. PubMed ID: 17460700
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells.
Lee SJ; Park HJ; Kim YH; Kim BY; Jin HS; Kim HJ; Han JH; Yim H; Jeong SY
Int J Mol Med; 2012 Aug; 30(2):443-50. PubMed ID: 22664653
[TBL] [Abstract][Full Text] [Related]
31. RNAi screening uncovers Dhx9 as a modifier of ABT-737 resistance in an Eμ-myc/Bcl-2 mouse model.
Mills JR; Malina A; Lee T; Di Paola D; Larsson O; Miething C; Grosse F; Tang H; Zannis-Hadjopoulos M; Lowe SW; Pelletier J
Blood; 2013 Apr; 121(17):3402-12. PubMed ID: 23440244
[TBL] [Abstract][Full Text] [Related]
32. MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors.
Hiraki M; Suzuki Y; Alam M; Hinohara K; Hasegawa M; Jin C; Kharbanda S; Kufe D
Sci Rep; 2016 May; 6():26643. PubMed ID: 27217294
[TBL] [Abstract][Full Text] [Related]
33. Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction.
Lickliter JD; Cox J; McCarron J; Martinez NR; Schmidt CW; Lin H; Nieda M; Nicol AJ
Br J Cancer; 2007 Feb; 96(4):600-8. PubMed ID: 17311012
[TBL] [Abstract][Full Text] [Related]
34. Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies.
Bogenberger JM; Delman D; Hansen N; Valdez R; Fauble V; Mesa RA; Tibes R
Leuk Lymphoma; 2015 Jan; 56(1):226-9. PubMed ID: 24707940
[No Abstract] [Full Text] [Related]
35. Histone deacetylase inhibitors are unable to synergize with ABT-737 in killing primary chronic lymphocytic leukaemia cells in vitro.
Ralli R; Banks KM; Wiegmans AP; Carney D; Seymour JF; Johnstone RW; Alsop AE
Leukemia; 2012 Jun; 26(6):1433-5. PubMed ID: 22289920
[No Abstract] [Full Text] [Related]
36. Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737.
Jayanthan A; Howard SC; Trippett T; Horton T; Whitlock JA; Daisley L; Lewis V; Narendran A
Leuk Lymphoma; 2009 Jul; 50(7):1174-82. PubMed ID: 19557638
[TBL] [Abstract][Full Text] [Related]
37. The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin.
Geserick P; Wang J; Feoktistova M; Leverkus M
Cell Death Dis; 2014 Sep; 5(9):e1412. PubMed ID: 25210795
[TBL] [Abstract][Full Text] [Related]
38. Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAF(V600E) inhibition and can be targeted to reduce resistance.
Serasinghe MN; Missert DJ; Asciolla JJ; Podgrabinska S; Wieder SY; Izadmehr S; Belbin G; Skobe M; Chipuk JE
Oncogene; 2015 Feb; 34(7):857-67. PubMed ID: 24608435
[TBL] [Abstract][Full Text] [Related]
39. Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo.
Soderquist R; Bates DJ; Danilov AV; Eastman A
Leukemia; 2013 Nov; 27(11):2262-4. PubMed ID: 23640104
[No Abstract] [Full Text] [Related]
40. Increased efficacy of CDDP in a xenograft model of hepatoblastoma using the apoptosis sensitizer ABT-737.
Lieber J; Dewerth A; Wenz J; Kirchner B; Eicher C; Warmann SW; Fuchs J; Armeanu-Ebinger S
Oncol Rep; 2013 Feb; 29(2):646-52. PubMed ID: 23229825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
